December 5-8, 2020; Online at https://www.hematology.org/meetings/annual-meeting
In the phase III UNITY-CLL trial, umbralisib + ublituximab demonstrated superior PFS benefit vs chlorambucil + obinutuzumab in both previously untreated and previously treated patients with CLL.